Lux Biosciences Expands Biomaterials Technology License From Rutgers University for Controlled Ocular Delivery of Pharmaceuticals

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that it has expanded its existing technology licensing agreement with Rutgers, The State University of New Jersey. The new agreement adds exclusive access for ophthalmic use to some of the University’s polycarbonate intellectual property estate, in addition to the polyarylate patent portfolio that Lux Biosciences licensed from Rutgers in September 2006. This additional technology platform gives Lux Biosciences access to a broader range of polymers that are all bioerodible and based on similar monomeric building blocks, which provides a broader range of features for the controlled long-term delivery of medications to the eye. Financial Terms of the agreement were not disclosed.